Show simple item record

dc.contributor.authorRUIZ BAÑOBRE, JUAN 
dc.contributor.authorAreses Manrique, María Carmen 
dc.contributor.authorMosquera-Martinez, J.
dc.contributor.authorCortegoso Mosquera, Alexandra Sabela 
dc.contributor.authorAfonso-Afonso, F. J.
dc.contributor.authorDE DIOS ALVAREZ, NOEMI 
dc.contributor.authorFernández Nuñez, Natalia 
dc.contributor.authorAZPITARTE RAPOSEIRAS, CRISTINA 
dc.contributor.authorAmenedo, M.
dc.contributor.authorSantome, L.
dc.contributor.authorFirvida Perez, Jose Luis 
dc.contributor.authorGarcía Campelo, María del Rosario 
dc.contributor.authorGarcía González, Jorge José 
dc.contributor.authorCasal Rubio, Joaquín 
dc.contributor.authorVázquez Estévez, Sergio 
dc.date.accessioned2021-11-23T09:14:08Z
dc.date.available2021-11-23T09:14:08Z
dc.date.issued2019
dc.identifier.issn2218-6751
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976357/pdf/tlcr-08-06-1078.pdfes]bi
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/32010585es]bi
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15728
dc.description.abstractThe lung immune prognostic index (LIPI) has been proposed as a new categorical blood-based biomarker to select advanced non-small cell lung cancer (NSCLC) patients for anti-programmed cell death-1 (PD-1) or programmed death ligand 1 (PD-L1) therapy. In this study, we investigate for the first time to the best of our knowledge the prognostic and predictive utility of the LIPI in a multicenter nivolumab monotherapy-based cohort. We retrospectively analyzed the influence of the baseline LIPI on overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and overall response rate (ORR) among 153 patients of a cohort of 188 advanced NSCLC patients treated with nivolumab in the second line of therapy or beyond. Worse LIPI was significantly associated with shorter OS in univariate [hazard ratio (HR) =3.12, 95% confidence interval (CI), 2.12-4.60; P<0.0001] and multivariate (HR =3.67, 95% CI, 1.96-6.86; P<0.0001) analyses. Worse LIPI was associated with shorter PFS (HR =1.45, 95% CI, 1.05-2.03; P=0.03), but this correlation did not reach statistical significance in multivariate analysis (HR =1.49, 95% CI, 0.94-2.38; P=0.09). Worse LIPI was associated with lower DCR in univariate [odds ratio (OR) =0.41, 95% CI, 0.24-0.70; P=0.001] and multivariate (OR =0.44, 95% CI, 0.25-0.78; P=0.005) analyses. This study confirms the utility of the LIPI in prognostication and disease control prediction in advanced NSCLC patients treated with nivolumab in the second line of therapy or beyond.es
dc.language.isoenges
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleEvaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapyes
dc.typeArtigoes
dc.authorsophosRuiz-Banobre, J.
dc.authorsophosAreses-Manrique, M. C.
dc.authorsophosMosquera-Martinez, J.
dc.authorsophosCortego, A.
dc.authorsophosAfonso-Afonso, F. J.
dc.authorsophosde Dios-Alvarez, N.
dc.authorsophosFernandez-Nunez, N.
dc.authorsophosAzpitarte-Raposeiras, C.
dc.authorsophosAmenedo, M.
dc.authorsophosSantome, L.
dc.authorsophosFirvida-Perez, J. L.
dc.authorsophosGarcia-Campelo, R.
dc.authorsophosGarcia-Gonzalez, J.
dc.authorsophosCasal-Rubio, J.
dc.authorsophosVazquez, S.
dc.identifier.doi10.21037/tlcr.2019.11.07
dc.identifier.pmid32010585
dc.identifier.sophos31482
dc.issue.number6es
dc.journal.titleTranslational lung cancer researches
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ferrol – Complexo Hospitalario Universitario de Ferrol::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario de A Coruña::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ourense, Verín e O Barco de Valdeorras - Complexo Hospitalario Universitario de Ourense::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Vigo - Complexo Hospitalario Universitario de Vigo::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Lugo, Cervo e Monforte de lemos - Complexo Hospitalario Universitario Lucus Augusti::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Pontevedra e O Salnés - Complexo Hospitalario Universitario de Pontevedra::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)es
dc.page.initial1078es
dc.page.final1085+es
dc.rights.accessRightsopenAccesses
dc.subject.keywordCHUFes
dc.subject.keywordCHUACes
dc.subject.keywordCHUSes
dc.subject.keywordCHUOes
dc.subject.keywordCHUVIes
dc.subject.keywordHULAes
dc.subject.keywordCHUPes
dc.subject.keywordIDISes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number8es


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International